Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

NCT02315625 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

NIH

Sponsor class

Stopped Study closed due to poor accrual.

Conditions

Neuroendocrine Tumors
Neuroendocrine Carcinoma
Neuroendocrine Neoplasms
Carcinoma, Neuroendocrine
Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

Interventions

DRUG: Sunitinib
DRUG: Everolimus

Sponsor

National Cancer Institute (NCI)